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Abstract
Background: Hypertension is a public health problem and a major risk factor for cardiovascular disease. The
purpose of this study is to compare the effectiveness of a multidisciplinary program based on group and individual
care versus group-only care, to promote blood pressure control in hypertensive patients in primary health care.
Methods: Randomized controlled clinical trial. The study was conducted within the primary health care, in two
units of the Family Health Strategy, covering 11,000 individuals, in Porto Alegre, Brazil. Two hundred and 56
patients, older than 40 years old and with uncontrolled hypertension, systolic blood pressure (BP) ≥140 mmHg
and/or diastolic BP ≥90 mmHg or ≥130 mmHg and/or diastolic BP ≥80 mmHg for individuals with diabetes.
Eligible patients were randomly assigned to a health care program aiming for blood pressure control, with the
multidisciplinary program group or with the multidisciplinary program plus personalized care group. Primary
outcome measures were reduction in systolic BP from baseline to 6 months. Secondary measures included
proportion of patients with systolic or diastolic BP controlled. Student t test, Pearson’s chi-squared test, Fisher’s
exact test, Mann-Whitney U test, Wilcoxon signed-ranks test and generalized estimating equation (GEE) model
were used in the analysis.
Results: The baseline characteristics of participants were similar between groups. After 6 months of follow-up,
systolic BP decreased markedly in both groups (Δ - 11.8 mmHg [SD, 20.2] in the multidisciplinary program group
and Δ - 12.9 mmHg [SD, 19.2] in the personalized care group; p < 0.001). Similarly, we noted a significant change in
diastolic BP over time in both groups (Δ - 8.1 mmHg [SD, 10.8] in the multidisciplinary program group and Δ - 7.
0 mmHg [SD, 11.5] in the personalized care group; p < 0.001).
Conclusions: The study demonstrates similar effectiveness of a group intervention in comparison to a personalized
education program in hypertension patients to achieve BP control. These findings indicate that the intervention can
be for all hypertensive patients assisted in primary health care.
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Background
Hypertension is a public health problem throughout the
world, affecting more than one billion people [1, 2]. The
estimated prevalence in developing countries is 40 %, in
comparison to 35 % in developed nations [3]. Studies
indicate that reductions of 10 mmHg to 12 mmHg in
systolic blood pressure (BP) or 5 mmHg to 6 mmHg in
diastolic BP, or both, lower the risk of stroke by 35 to
40 %, cardiovascular death by 20 to 25 %, coronary heart
disease by 14 to 16 %, and heart failure by 50 % [4–11].
In spite of well-established benefits of low BP, and the
existence of several national and international guidelines
on diagnostic and management of hypertension, control
remains poor [12]. Canada has the lowest prevalence of
hypertension at 19 %, followed by England and the
United States of America (USA) at about 30 % each.
However, only 34 % had BP under 140/90 mmHg in
England, compared with 50 % in the USA and 66 % in
Canada [13]. These numbers are even worse in develop-
ing countries, where hypertension prevalence is higher.
In Brazil, approximately 30 % of adults are hypertensive
[14], and BP control rates are even lower, ranging from
57.6 % to around 10 % [15, 16].
Health promotion programs related mainly to medica-
tion adherence, diet, physical activity and smoking habit
have been introduced in different countries for preven-
tion and control of cardiovascular risk factors [17].
Regarding the prevention of cardiovascular disease
(CVD) in Brazil, the importance of public policies
directed at nutrition and physical activity has been
highlighted in the last few years. The National Diet and
Nutrition Policy and the adoption of the Global Strategy
on Healthy Eating, Physical Exercise and Health, of the
World Health Organization (WHO) are examples of
public policies, which include recommendations regard-
ing healthy eating as a way to control and prevent CVD
in primary health care (PHC) level [17, 18].
The Family Health Program and the Support Nucleus
for the Family Healthcare (multidisciplinary program)
are priority strategies of the Ministry of Health in order
to organize PHC in Brazil [19]. It is believed that these
strategies are adequate models for addressing CVD by
means of prevention and health promotion, aimed to
change the behavior and living habits of individuals,
without losing sight of the interactions in collective and
social spheres [20, 21]. However, no study has evaluated
the effects of these programs in chronic disease patients,
especially compared with other valid approaches. In this
context, the objective of this study was to evaluate the
effectiveness of a multidisciplinary program in PHC to
promote BP control in hypertensive patients.
Methods
Study design and setting
The study was designed as a randomized, controlled
clinical trial. It was conducted in two units under the
Family Health Strategy (FHS), in Restinga and Extreme-
South districts of Porto Alegre, Southern Brazil. These
FHS units cover 11,000 individuals and Restinga is a
low-income district, with approximately 100,000 people
and a Human Development Index (HDI) of 0,700–
0,799 [22].
Participants
Patients were eligible for inclusion in the study if they
were older than 40 years old, with previous hypertension
diagnosis, and BP levels above recommended, measured
by nurse technicians in screening in the FHS unit.
Uncontrolled BP was defined as systolic BP ≥140 mmHg
and /or diastolic BP ≥90 mmHg or ≥130 mmHg and /or
diastolic BP ≥80 mmHg for individuals with diabetes
[12, 23]. Institutionalized patients, with mental illnesses
or disabling chronic illnesses, patients who were exclu-
sively assisted by health insurance and those with a life
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expectancy of less than a year were not included in the
study. Also, none of the participants could have been
involved in a physical training program or a lifestyle
change for 6 months prior to the study.
Screening and recruitment
All patients who were assisted by a Family Health Team
(FHT) with uncontrolled BP from May to July 2013 were
invited to participate in the study. Eligible participants
were identified through active screening by a research
assistant. Three BP measures were performed according
to the study protocol, using an appropriately sized cuff
and a calibrated automated device with memory for
storage of measurements (Omron HEM - 742 INT Intel-
liSense; Omron Healthcare) in the sitting position, after
five minutes of rest, with no less than 1 min between
measurements. The average of the second and third
measures was used [12, 23].
Interventions
Health professionals education
Health care professionals in the FHT (physicians, nurses,
social workers) were invited to receive training, aiming
to standardized care. The first training, which lasted
90 min, was performed by a cardiologist who focused on
standard treatment algorithms for hypertension care and
management, which were based on the Seventh Report
of the Joint National Committee on Prevention, Detec-
tion, Evaluation, and Treatment of High Blood Pressure
Guidelines (JNC 7) and the VI Brazilian Guidelines on
Hypertension [12, 23].
Another training, which involved all professionals in
the FHT, was conducted by a pharmacist, a dietitian and
a physical educator who addressed no pharmacologic
components (diet, exercise, weight loss, smoking cessa-
tion, and other recommendations) and pharmacologic
interventions (prescription of drugs provided by the
Unified Health System - UHS, and low-cost).
Manuals for health education were designed, based on
evidence, for the four main areas of interest: pharma-
ceutical care (prepared considering the availability of
drugs in public pharmacies), nutrition, physical activity,
and strategies to be adopted in groups. These manuals
were created in order to assist professionals during the
study period, and also for the FHT to continue the
personalized assistance with patients.
Patients education baseline
All patients included in the study were invited to partici-
pate in educational health workshops, with a dietitian, a
physical educator, a pharmacist, and at least one mem-
ber of the FHT. In these workshops, all participants
were oriented to BP control, and received guidance on
the benefits of having a healthy life and the deleterious
effects of hypertension. The importance of achieving BP
targets and adhering to medication was emphasized.
After this activity, patients were randomized to the
multidisciplinary program in the family healthcare
group or multidisciplinary program plus personalized
care group.
Multidisciplinary program for the family healthcare group
Multidisciplinary healthcare teams were established by
Ordinance of the Ministry of Health, Decree No. 154 of
January 24, 2008, under the name of the Support
Nucleus for the Family Healthcare [19]. According to
the Ministry, these programs should be performed by
teams composed of different health care professionals, to
support and to work in partnership with FHT with a
focus on health practices in territories under their
responsibility. The team who participated in this study
consisted of a physical educator, a pharmacist and a
dietitian, with the goal to promote adherence to drug
treatment, to plan a balanced diet and to encourage the
practice of physical activity. The activities offered by the
multidisciplinary program were of standard care, and for
this study the multidisciplinary program was considered
the control group.
The multidisciplinary program group participated in
monthly health education instruction and engaged in
physical activity twice a week. Health education work-
shops were conducted in different locations for each of
the geographical areas, to facilitate participants’ access,
in places such as churches, halls, parks, schools and the
participants’ residence.
The workshops covered topics related to hypertension
through lectures and interactive dynamics, using posters,
pictures, videos and practical demonstrations (concept,
risk factors and treatment); physical activity (benefits
and importance of weight reduction or maintenance, as
well as improvement in quality of life and daily activities
performance, they were also trained to perform the
physical activities at home); medication adherence and
dietary measures (consumption of fat, sugar and salt,
recommendation and dangers of excessive consumption,
and incentive to consume fruits and vegetables). Differ-
ent kinds of fruits and vegetables were taken to the
statement of recommended serving size and description
of their beneficial health properties was made available.
The participants were provided with systematic but
flexible guidance, according to the needs and financial
conditions of each of them.
A physical educator, in the presence of a pharmacist
or a dietitian, and a member of the FHT, conducted a
twice-a-week aerobic exercise training. The participants’
heart rate and BP were always measured at the begin-
ning and the end of the activity. Each exercise session
comprised an initial 5-min warm up, 50-min aerobic
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exercises and a final 5-min cool down phase. The phys-
ical activities also had a playful and relaxing profile.
Multidisciplinary program plus personalized care group
In addition to the group activities offered by the multi-
disciplinary program, the personalized care group (inter-
vention group) also received referral to visit a dietitian
and a clinical pharmacist with focus on hypertension
control. A dietary approach was planned according to
nutritional needs, socioeconomic status, and individual
dietary habits. A 24-h dietary recall (24 h-DR) was
applied in the 1st, 3rd and 6th month for assessment of
dietary habits.
Counseling from the pharmacist included information
about proper medication administration, side effects,
and disease education. Pharmacists also reviewed pa-
tients’ medications and prescriptions by completing
medication reconciliation; identifying duplicate, un-
necessary, or incomplete therapy; checking for drug
interactions; verifying patients’ formulary drug coverage
and medications availability; and ensuring prescription
completeness. To minimize variability during the coun-
seling process, a standardized checklist was developed
outlining the topics to be covered during a session, and
standardized patient education leaflets were used. In
order to identify the number of times each drug had to
be taken, medication reconciliation was used, which
included the names of all the drugs prescribed, with
figures corresponding to the moment in which it had to
be taken each time. The same illustrative figure was
placed in the box of the product.
Patients were encouraged to check BP at home, and
an automatic digital arm pressure monitor with memory
for storage of measurements (Omron®, model HEM
742I) was provided twice, during the study period. Dur-
ing the appointment with the pharmacist, patients were
trained and instructed to check BP twice a day for five
days [24]. For individuals with diabetes, glucometers and
test strips (Accu-Check®) for glucose control were
provided during the entire study period.
Measurement and data collection
The primary outcome at 6th month was systolic BP
reduction from baseline to the last follow-up visit. The
secondary outcome was diastolic BP reduction from
baseline to the last follow-up and the proportion of par-
ticipants with controlled BP, <140 mmHg for systolic BP
or <90 mmHg for diastolic BP and <130 mmHg for
systolic BP or diastolic BP <80 mmHg for individuals
with diabetes [12].
Other important patient data included demographic
(gender, age, race and marital status), socioeconomic
(education level and social class, according to the
classification of the Brazilian Association of Research
Companies - BARC [25]), and behavioral variables
(smoking, alcohol consumption and physical activity).
The Alcohol Use Disorders Identification Test (AUDIT)
was applied to assess alcohol consumption, and the
International Physical Activity Questionnaire (IPAQ)
was used to evaluate the level of physical activity
[26–28]. Height, weight, waist circumference and hip
circumference were measured and the body mass
index (BMI) was calculated [29].
The medication adherence was measured using two
validated questionnaires in Portuguese: the Morisky-
Green Test with four questions, and the Brief Medication
Questionnaire (BMQ) with eleven questions [30–32]. The
Charlson Comorbidity Index (CCI) was used to assess the
presence of comorbidities. The absolute number for each
condition identified was considered [33]. The Biochemical
profile was assessed only at the end of the study, and
included measurements of total cholesterol, high-density
lipoprotein cholesterol (HDL), triglycerides, and low-
density lipoprotein cholesterol (LDL), fasting blood
glucose (FBG) and glycated hemoglobin (HbA1c) levels
for individuals with diabetes, all with a 12-h fast. LDL-C
was calculated using the Friedewald formula for those
with triglycerides levels < 400 mg/dL [34].
For assessment of global cardiovascular risk we used the
Framingham Risk Score (FRS) for nondiabetic individuals
and the UKPDS Risk Engine (United Kingdom Prospect-
ive Diabetes Study) for individuals with diabetes [35, 36].
According to the FRS, patients were classified as low risk
<10 %, intermediate risk 10–20 % and high risk > 20 %
probability of cardiovascular event in 10 years.
Randomization
The randomization sequence was computer-generated
and was assigned by a member of the study team who
was blind to patient assignment until the intervention.
Block randomization was used, with random block sizes
of four, six and eight, in order to ensure similar size
among the groups. During the study period, patients and
health team members were aware of allocated groups.
The randomization list was concealed in a central office.
Statistical analysis
A sample of 127 participants in each trial group (overall
of 254) was planned, with an 80 % power, and a p-value
of 0.05, to detect a reduction of 7.2 mmHg in systolic BP
with standard deviation (SD) 20.45 mmHg in the inter-
vention group and SD 20.26 mmHg in the control group
[37]. Continuous variables are expressed as mean and
SD or median interval interquartile (IQR), and categor-
ical variables are expressed as proportions.
The groups were compared by means of the Student t
test for continuous variables, and the Pearson’s chi-
squared test or the Fisher’s exact test for categorical
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variables. The Mann-Whitney U test was used in
between-group comparisons for variables not normally
distributed. The Wilcoxon signed-ranks test for paired
samples was used in within-group comparisons. Con-
tinuous variables taken at different time intervals were
compared by generalized estimating equation model
(GEE) to evaluate the effect of group allocation, adjust-
ing for time effect (group * time). The variables were
treated as normal distribution, with a connection iden-
tity function. The working correlation matrix used was
unstructured and robust estimator covariance matrix.
For significant effects was used post-hoc Bonferroni.
Analysis of variance for linear trend was used to com-
pare the reduction of BP in different levels of physical
activity and medication adherence. Control for con-
founding factors regarding the reduction of BP levels
was performed by multivariate linear regression analysis.
For evaluation of medication adherence, the categories
of BMQ were grouped into: high adherence and prob-
ably high adherence, and probably low adherence and
low adherence. P values < 0.05 were considered statisti-
cally significant. All analyses were completed using the




The study was conducted from July to December 2013.
Among the 280 screened individuals, 256 (91 %) were
considered eligible and were included in the study, 128
were randomly assigned to the multidisciplinary pro-
gram group, and 128 to the personalized care group
(Fig. 1). At the 6th month of the study, 16 patients were
excluded from the multidisciplinary program group, due
to the following reasons: five lost contact, six of them
changed their addresses and three died, and 15 patients
were excluded from the personalized care group: seven
lost contact, seven changed their addresses and one died.
The causes of death were acute myocardial infarction
(AMI), stroke and gunshot in the multidisciplinary pro-
gram group and AMI in the personalized care group.
Baseline characteristics
Patients in each study group had similar baseline character-
istics in respect to age, gender, education, BMI, smoking
status, prevalence, baseline blood pressure and presence of
chronic illness, with the exception of congestive heart
failure history, more frequent in the control group. Most
patients in the study (84 % for multidisciplinary program
Fig. 1 Study flow diagram
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group and 83 % for personalized care group) had at least
score ≥1 comorbidity of the Charlson Index; and 23 % of
the patients in the multidisciplinary program group and
27 % in the personalized care group had diabetes (Table 1).
Blood pressure and hypertension control
During the study period, systolic BP decreased in both
treatment groups, Δ - 11.8 mmHg (SD, 20.2) in the
multidisciplinary program group, (p < 0.001) and Δ -
12.9 mmHg (SD, 19.2) in the personalized care group,
(p < 0.001), with no significance between the groups,
p = 0.60. Similarly, a significant change in diastolic BP
was also noted in respect to time in both groups, Δ -
8.1 mmHg (SD, 10.8) in the multidisciplinary program
group (p < 0.001) and Δ - 7.0 mmHg (SD, 11.5) in the
personalized care group (p < 0.001), and no significance
between groups was observed, p = 0.36 (Table 2). In the
secondary outcome analysis, a significant increase in the
proportion of patients with controlled systolic and dia-
stolic BP (p < 0.001) was detected, between baseline and
6-months in both groups (Table 3). In addition, the rela-
tive risk of not achieving the systolic BP target in indi-
viduals with diabetes was 1.64 times higher than in
nondiabetics (95 % CI 1.33 to 2.03) and 2.87 in diastolic
BP (95 % CI 1. 87 to 4.41).
Pharmacological treatment and medication adherence
The pharmacologic treatment during the study was simi-
lar for all drug classes. The number of antihypertensive
medication prescribed was similar in both groups in the
baseline (multidisciplinary program group 83 % vs.
personalized care group 83 %, p = 0.74), and did not in-
crease significantly over time (multidisciplinary program
group 86 % vs. personalized care group 88 %, p = 0.85).
Although subjects of both groups were prescribed more
antihypertensive drugs, this increase was similar between
groups (multidisciplinary program group p = 0.29 and
personalized care group, p = 0.06) (Table 4). Both in the
multidisciplinary program group and in the personalized
care group there was a percentage of patients without
drug prescription, and this condition did not change
between and within groups at the end of the study,
p = 0.98. Medication adherence measured by the
Morisky-Green Test increased from 34 to 49 % in the
multidisciplinary program group and from 35 to 55 % in
the personalized care group. In relation to the BMQ test,
the medication adherence increased from 35 to 68 % in
the multidisciplinary program group and from 22 to 67 %
in the personalized care group. There was no significant
difference between groups in both tests (Table 5).
Physical activity
The amount of physical activity performed increased in the
multidisciplinary program group and in the personalized
care group; p < 0.001. In addition, the percentage of active
people increased from 22 to 49 % in the multidisciplinary
program group (p < 0.001), and from 21 to 52 % in the
personalized care group (p < 0.001). However, there was no
significant difference between groups. In the linear trend
analysis, patients classified as active by IPAC had a
greater BP control; systolic BP (p = 0.043), diastolic BP
(p = 0.039), but when adjusted for gender and medica-
tion adherence, only medication adherence remained
significant (p = 0.027).
Anthropometric measures, biochemical profile and
cardiovascular risk
Regarding anthropometric measures, no differences were
observed between the groups in variables such as BMI,
waist circumference (WC) and waist-to-hip ratio (WHR)
within 6 months (Table 2). BP self-monitoring in both
groups increased over time, p = 0.001, but there was no
difference between groups, p = 0.473 (Table 4). The
results of biochemical profile and of cardiovascular risk
are shown on Table 6. Biochemical tests were not
available for most patients at baseline; therefore, only
6-month values are presented. The groups did not
significantly differ at the end of the study, regarding
biochemical profile and cardiovascular risk, both in
individuals with and without diabetes (Table 6). The
percentage of smoking and alcohol consumption de-
creased in both groups, but it was not of significance
(data not shown).
Dietary assessment
There were no statistically significant differences in total
calories intake, macronutrients (carbohydrate, protein
and total lipids), saturated fat acid (SFA), polyunsatur-
ated fat acid (PFA) and monounsaturated fat acid (MFA)
between groups after the intervention. Similarly, choles-
terol, micronutrients (calcium, iron and potassium),
fibers and sodium did not differ significantly. Regarding
fruit ingestion, there was a significant higher consump-
tion in the personalized care group (data not shown).
Discussion
In this study we evaluated the effectiveness of a multi-
disciplinary program, suggested by the Ministry of
Health, to promote BP control in hypertensive patients
in PHC, in Brazil. The results of this study show that
among adults with uncontrolled BP, an education strat-
egy with multidisciplinary program alone or combined
with personalized care in BP management reduced
systolic and diastolic BP significantly and increased the
proportion of patients with BP on target.
Our educational program resulted in 11.8 mmHg and
12.9 mmHg reductions in systolic BP in both multidis-
ciplinary program group and personalized care groups,
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Table 1 Sociodemographic, clinical and behavioral characteristics of participants
Characteristic Group
Multidisciplinary Program Personalized Care p-value
n = 128 n = 128
Gender, male 40 (31) 35 (27) 0.583a
Age, years 60 ± 11 59 ± 10 0.527b
Race
White 98 (77) 95 (74) 0.652a
Yellow 17 (13) 22 (17)
Black 13 (10) 11 (9)
Years of education completed
0 – 4 62 (48) 59 (46) 0.410a
5 – 8 41 (32) 50 (39)
≥ 9 25 (20) 19 (15)
Marital status
Married 74 (58) 78 (61) 0.364a
Single 14 (11) 8 (6)
Separated 13 (10) 19 (15)
Widowed 27 (21) 23 (18)
Social class, BARC
High, A/B 37 (29) 33 (26) 0.277a
Medium, C 62 (48) 74 (58)
Low, D/E 29 (23) 21 (16)
BMI, Kg/m2 30 ± 0.5 30 ± 0.5 0.784b
Blood pressure, mmHg
Systolic 156 ± 2 158 ± 2 0.437b
Diastolic 89 ± 1 90 ± 1 0.633b
Comorbidity Index
CCI 2 (1–3) 2 (1–4) 0.704c
CCI-Y 4 (2–5) 3 (2–5) 0.951c
CIC-Y, survival 10 years 53 (11–85) 56 (16–82) 0.843c
Comorbidity
Previous myocardial infarction 16 (13) 10 (8) 0.214a
Heart failure 22 (17) 11 (9) 0.040a
Peripheral vascular disease 13 (10) 13 (10) 1.000a
Stroke 18 (14) 17 (13) 0.856a
Diabetes Mellitus 32 (23) 34 (27) 0.564a
COPD 9 (7) 5 (4) 0.272a
Connective tissue disease 57 (45) 69 (54) 0.134a
Gastric ulcers 24 (19) 24 (19) 1.000a
Liver disease 12 (9) 13 (10) 1.000a
Renal disease 17 (13) 20 (16) 0.594a
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Table 1 Sociodemographic, clinical and behavioral characteristics of participants (Continued)
Cancer 10 (8) 5 (4) 0.237a
Smoking status
Never 50 (43) 52 (47) 0.563a
Current 25 (21) 20 (18)
Past 42 (36) 38 (35)
BARC Brazilian association of research companies, BMI Body mass index, CCI Charlson comorbidity index, CCI-Y Charlson comorbidity-year index, COPD Chronic
obstructive pulmonary disease. Values expressed n (%), mean and standard error (SE) or median and interquartile range (IQR)
aPerson chi-square test or Fisher’s exact test
bStudent’s t-test
cMann-Whitney U test
Table 2 Blood pressure and clinical measurements from baseline to end of study
Variable Group p-value
Multidisciplinary Program Personalized Care Group Time Interaction
n = 113 n = 114
Systolic BP, mmHg
Baseline 156 ± 1.6 (128) 158 ± 1.8 (128) 0.575 <0.001 0.600
6 Months 144 ± 1.8 (114) 143 ± 1.8 (113)
Δ - 11.8 ± 20.2 - 12.9 ± 19.2
Diastolic BP, mmHg
Baseline 89 ± 1.02 (128) 90 ± 1.03 (128) 0.286 <0.001 0.365
6 Months 80 ± 1.03 (114) 82 ± 1.09 (113)
Δ - 8.10 ± 10.8 - 7.0 ± 11.5
BMI, Kg/m2
Baseline 29.9 ± 0.5 (128) 30.1 ± 0.5 (128) 0.745 0.454 0.859
6 Months 30 ± 0.5 (114) 30.2 ± 0.5 (113)
Δ 0.08 ± 1.9 0.13 ± 2.9
WC, cm
Baseline 95.1 ± 1.7 (127) 96.1 ± 1.2 (126) 0.438 0.122 0.608
6 Months 95.6 ± 1 (113) 96.9 ± 1.1 (113)
Δ 0.40 ± 5.9 0.82 ± 6.6
WHR
Baseline 0.91 ± 0 (127) 0.92 ± 0 (126) 0.482 0.098 0.482
6 Months 0.90 ± 0 (113) 0.91 ± 0 (113)
Δ - 0.012 ± 0.06 - 0.003 ± 0.88
Appointments, number
Baseline 3.82 ± 0.4 2.95 ± 0.2 0.258 <0.001 0.084
6 Months 1.9 ± 0.2 2.02 ± 0.2
Δ - 1.94 ± 0.4 - 0.93 ± 0.3
Physical activity, min per week
Baseline 87 ± 12 96 ± 14 0.114 <0.001 0.110
6 Months 188 ± 17 245 ± 27
Δ 103 ± 15 151 ± 26
BP Blood pressure, BMI Body mass index, WC Waist circumference, WHR Waist-to-hip ratio. Values expressed n (%), mean and standard error (SE), GEE Generalized
estimating equationan overview of five randomized controlled
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respectively. For nondiabetic individuals, rates of systolic
BP under control were of 8.6 to 49.4 % in the multidis-
ciplinary program group and of 6.6 to 57.1 % in the
personalized care group. In individuals with diabetes, the
systolic BP control was of 0 to 27 % in the multidiscip-
linary program group and of 0 to 22.2 % in the perso-
nalized care group. Our control rate was lower in
individuals with diabetes than in nondiabetic individuals;
however, literature data indicate that the rate control in
these individuals could be as low as 3 %, similar to find-
ings at the beginning of this study [38].
A systematic review of 24 observational studies includ-
ing 47,964 individuals, with both hypertension and
diabetes, reported that only 12 % (range 6 to 30 %) of
participants had controlled BP [39].
Our study showed significant BP reductions in both
groups without alterations on medications prescribed.
There are some potential explanations for the good BP
results, including BP goal reinforcement by the educa-
tion program, medication adherence and lifestyle modifi-
cations, as well as regular physical activity practice.
Increased adherence to medications probably played an
important role in the results observed. In the study of
Guiraro et al. [40], the treatment adherence measured
by the Morisky-Green Test increased by 9.6 % in the
intervention group and 8.8 % in the control group. The
intervention consisted of personalized information by a
trained nurse and written leaflets and the individuals
allocated to the control group received the usual clinical
care without any standardized intervention. In our study,
Table 3 Blood pressure control from baseline to end of study
Variables Group
Multidisciplinary Program Personalized Care Between group
Baseline 6 Months p-value Baseline 6 Months p-value Baseline 6 Months
n = 128 n = 113 n = 128 n = 114 p-value
Systolic BP
Nondiabetic 7 (9) 40 (49) <0.001 5 (7) 44 (57) <0.001 0.451 0.744
Diabetic 0 (0) 9 (27) 0.003 0 (0) 8 (22) 0.014
Diastolic BP
Nondiabetic 37 (47) 68 (86) <0.001 36 (47) 62 (81) <0.001 0.697 0.473
Diabetic 6 (18) 17 (52) 0.003 5 (14) 19 (53) <0.001
BP blood pressure. BP control defined as systolic BP <140 or diastolic BP 90 mmHg for nondiabetic patients and systolic BP level <130 mmHg or diastolic
BP <80 mmHg for diabetic patients. Values expressed n (%). Person chi-square test
Table 4 Pharmacologic treatment
Variable Multidisciplinary Program Personalized Care Between groups
Baseline 6 Months p-value Baseline 6 Months p-value Baseline 6 Months
n = 128 n = 113 n = 128 n = 114 p-value
Medication class
Not prescription 5 (4) 9 (8) 0.289 13 (12) 10 (8) 0.453 0.084 0.984
Antihypertensives 94 (83) 98 (86) 0.289 94 (83) 99 (88) 0.063 0.743 0.845
Antidiabetic 29 (26) 30 (27) 1.000 31 (28) 34 (31) 0.508 0.388 0.558
Antidepressive agents 27 (24) 25 (22) 0.880 34 (30) 29 (26) 0.533 0.322 0.536
Other cardiovascular drugs 36 (32) 40 (35) 0.481 45 (40) 5 (40) 1.000 0.090 0.095
Pulmonary 5 (5) 6 (5) 1.000 6 (6) 7 (6) 1.000 0.769 0.784
Hypolipidemic agents 36 (32) 40 (35) 0.503 39 (35) 41 (37) 0.774 0.687 0.890
Antihypertensive drugs
Diuretics 49 (44) 55 (49) 0.286 49 (44) 59 (53) 0.052 1.000 0.592
Beta blockers 31 (27) 38 (34) 0.118 35 (32) 39 (36) 0.424 0.342 1.000
ACE 66 (58) 66 (58) 1.000 63 (57) 63 (57) 1.000 0.704 0.789
ARBs 10 (9) 13 (12) 0.508 17 (16) 23 (21) 0.70 0.079 0.150
CCB 19 (17) 22 (20) 0.453 15 (14) 21 (19) 0.146 0.486 0.867
ACE Angiotensin-converting enzyme inhibitor, ARBs Angiotensin II Receptor Blockers, CCB Calcium channel blockers. Values expressed n (%). Person chi-square test
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there was a 15 % increase in the multidisciplinary
program group and 20 % in the personalized care group.
Healthy life style, especially engagement in physical
activities was highly emphasized, and also could have
had some effect on BP control. The protocol required
that both groups practiced physical activity twice a week
and participated in health education workshops once a
month. It was demonstrated in a prior study that more
participants in the exercise group (56.7 %) than in the
control group (35.5 %) attained adequate BP control
(<140/90 mmHg) post-12-week interventions [41].
Although prior trials suggested that empowerment,
constant feedback and individualized care are more
effective in achieving medication and care adherence, in
our study the combination of these elements in the
personalized care did not translate into greater BP
control than in the multidisciplinary program. This re-
sult suggests that the activities conducted in groups
can be as effective as individual guidelines, if per-
formed accordingly.
No reductions were observed in anthropometric mea-
surements in our study. Similarly, in a cluster random-
ized controlled trial, Harris MF et al. [42], found a small
weight reduction (1.06 kg) that was achieved only among
those attending the intervention group, participating in
the education program. Improved glycemic control
reduced microvascular and macrovascular complications
associated with type 2 diabetes mellitus. At the 6th
month, we found an average of 6.6 mg/dL in the multi-
disciplinary program group and 6.4 mg/dL in the
personalized care group, in HbA1c. However, the lack of
baseline data precludes any conclusion regarding dia-
betes control in our population.
Self-care activities which help to control blood glucose
levels and to avoid diabetes-related complications are
important in diabetes treatment. Doucette et al. [43]
Table 5 Behavioral and medication adherence
Variable Group
Multidisciplinary Program Personalized Care Between groups
Baseline 6 Months p-value Baseline 6 Months p-value Baseline 6 Months
n = 128 n = 113 n = 128 n = 114 p-value
IPAC
Active 25 (22) 56 (49) 0.001 24 (21) 59 (52) <0.001 0.930 0.750
Insufficient active 39 (34) 40 (35) 41 (36) 40 (35)
Inactive 50 (44) 18 (16) 48 (43) 14 (12)
Considers health
Very bad 7 (6) 7 (6) 0.133 8 (7) 2 (2) 0.047 0.701 0.253
Bad 13 (11) 13 (11) 14 (12) 8 (7)
Regular 55 (48) 44 (39) 46 (41) 42 (37)
Good 38 (33) 45 (40) 42 (37) 53 (47)
Very Good 1 (1) 5 (4) 3 (3) 8 (7)
BP self-monitoring
Every day 16 (14) 28 (25) <0.001 13 (12) 21 (19) <0.001 0.532 0.473
Once week 28 (25) 29 (25) 22 (20) 38 (34)
Once month 19 (17) 42 (37) 20 (18) 36 (32)
Rarely 49 (43) 13 (11) 57 (50) 17 (15)
Never 2 (1.8) 2 (2) 1 (1) 1 (1)
BMQ
High adherence 35 (35) 69 (68) <0.001 21 (22) 64 (67) <0.001 0.093 0.996
Low adherence 66 (65) 32 (32) 75 (78) 32 (33)
TMG
Adherence 34 (34) 49 (49) 0.008 34 (35) 53 (55) <0.001 0.635 0.810
Moderate Adherent 55 (55) 47 (47) 44 (46) 39 (41)
Low adherence 12 (12) 5 (5) 18 (19) 4 (4)
Improved self-esteem 90 (79) 102 (90) <0.001
IPAC International Physical Activity Questionnaire, BP blood pressure, BMQ Brief Medication Questionnaire, TMG Test Morisky-Green, AUDIT Alcohol Use Disorder
Identification Test. Values are n (%). Person chi-square test
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observed, in a randomized clinical trial, that a pharmacist-
provided diabetes care service led to significant im-
provement in self-management and self-care activities
in individuals with diabetes. A main challenge for our
study was to motivate individuals to participate in the
activities proposed. Rates of attendance and comple-
tion of lifestyle programs are often poor and highly
variable in general practice [44].
This study was unable to determine the variables that
influenced the reduction of BP. However, it was designed
to assess the effect of an education program to promote
BP control in hypertensive individuals in PHC, not to
determine the mechanisms by which a reduction in BP
was achieved. It is believed that the benefit of an educa-
tion program on lowering BP was due to a combination
of strategies and not one isolated element, such as
changes in lifestyle, physical activity and greater medica-
tion adherence [45].
Some caveats of this study ought to be considered.
Firstly, variance in BP could have occurred because
observations within groups may have correlated, that is,
both groups were composed of people who visited the
same places, lived in the same neighborhood or nearby,
or may be more similar than those in different locations.
Secondly, the values of biochemical tests were not avail-
able at baseline, and it was believed that these patients
should have had several of these examinations in their
routine, but they were not available. Moreover, the
24 h-DR was not performed at baseline in the multi-
disciplinary program group, only at the 6th months.
This fact limits comparisons of groups at baseline
and at 6 months and it cannot be stated that dietary
data changed during the period.
Conclusions
The study demonstrates the effectiveness of a multidis-
ciplinary program intervention in BP control in the
setting of primary care. The combination of personalized
care, involving nutritionists and clinical pharmacists, did
not translate into additional benefit of achieving BP
control. These findings indicate that the model proposed
for the Family Health Program by the Support Nucleus
for the Family Healthcare (multidisciplinary program)
must be considered for all hypertensive patients assisted
in PHC. Other studies with longer period of follow up
should be conducted to evaluate the impact of these
interventions on clinical outcomes associated with bio-
chemical profile and cardiovascular risk.
Table 6 Cardiovascular risk factors at the end of the study
Variable Group
Multidisciplinary Program Personalized Care p-value
n = 113 n = 114
FBG, mg/dL
Diabetic 137 ± 52 (32) 135 ± 36 (33) 0.905a
Nondiabetic 92 ± 16 (68) 93 ± 15 (67) 0.712a
HbA1c, % 6.6 ± 2 (32) 6.4 ± 1 (33) 0.634a
Total cholesterol, mg/dL 191 ± 47 (107) 198 ± 47 (104) 0.263a
HDL, mg/dL 45 ± 12 (107) 45 ± 12 (104) 0.916a
LDL, mg/dL 113 ± 41 (96) 119 ± 41 (98) 0.297a
Triglyceride, mg/dL 143 (113 – 190) (107) 143 (112 – 213) (104) 0.769b
Nondiabetic, 10 years FRS, n%
Low 47 (63) 39 (55) 0.528c
Medium 19 (25) 24 (34)
High 9 (12) 8 (11)
Mean FRS 5 (2–14) 6 (3–14) 0.647b
Diabetic, UKPDS, risk 10 year, %
CHD 12 (8 – 17) (32) 11 (6 – 19) 0.572b
Fatal CHD 7 (4–10) (32) 6 (3 – 13) 0.682b
Stroke 7 (5 – 12) (32) 5.5 (3 – 12) 0.993b
Fatal Stroke 1 (1 – 2) (32) 1 (1 – 2) 0.992b
FBG Fasting blood glucose, HbA1c Glycated hemoglobin, HDL High-density lipoprotein, LDL Low-density lipoprotein cholesterol, FRS Framingham risk score, CVD
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